共 50 条
- [1] PRETREATMENT EGFR T790M MUTATION AND BRCA1 MRNA EXPRESSION IN ERLOTINIB-TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) WITH EGFR MUTATIONS[J]. ANNALS OF ONCOLOGY, 2010, 21 : 129 - 129Rosell, R.Molina, M. A.Costa, C.Bertran-Alamillo, J.Mayo, C.Moran, T.Viteri, S.Mendez, P.Benlloch, S.Taron, M.
- [2] Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations[J]. CLINICAL CANCER RESEARCH, 2011, 17 (05) : 1160 - 1168Rosell, RafaelAngel Molina, MiguelCosta, CarlotaSimonetti, SaraGimenez-Capitan, AnaBertran-Alamillo, JordiMayo, ClaraMoran, TeresaMendez, PedroCardenal, FelipeIsla, DoloresProvencio, MarianoCobo, ManuelInsa, AmeliaGarcia-Campelo, RosarioReguart, NoemiMajem, MargaritaViteri, SantiagoCarcereny, EnricPorta, RuthMassuti, BartomeuQueralt, Cristinade Aguirre, ItziarMiguel Sanchez, JoseSanchez-Ronco, MariaLuis Mate, JoseAriza, AurelioBenlloch, SusanaJavier Sanchez, JoseBivona, Trever G.Sawyers, Charles L.Taron, Miquel
- [3] Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Rosell, R.Molina, M. A.Costa, C.Taron, M.Bertran-Alamillo, J.Mayo, C.Benlloch, S.Moran, T.Cardenal, F.Porta, R.
- [4] A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S711 - S712Stahel, R. A.Dafni, U.Gautschi, O.Felip, E.Curioni-Fontecedro, A.Peters, S.Massuti, B.Cardenal, F.Aix, S. P.Frueh, M.Pless, M.Popat, S.Kotsakis, A.Cuffe, S.Bidoli, P.Favaretto, A.Carcereny, E.Sanchez Ronco, M.Molina, M. A.Rosell, R.
- [5] ROR1 mRNA expression in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with the T790M mutation: A potential therapeutic target[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Karachaliou, NikiDrozdowskyj, AnaCosta, CarlotaAngel Molina-Vila, MiguelGimenez Capitan, AnaVergnenegre, AlainMassuti, BartomeuMoran, TeresaMajem, MargaritaFelip, EnriquetaCarcereny Costa, EnricRosario Garcia-Campelo, M.Viteri Ramirez, SantiagoNicole Heidecke, CordulaEstrada-Tejedor, RogerTeixido, JordiGrant Bivona, TreverGiannikopoulos, PetrosOno, MayumiRosell, Rafael
- [6] BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients with EGFR Mutations[J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 295 - 300Karachaliou, NikiCosta, CarlotaGimenez-Capitan, AnaAngel Molina-Vila, MiguelBertran-Alamillo, JordiMayo, ClaraMassuti, BartomeuMajem, MargaritaCarcereny, EnricMoran, TeresaJavier Sanchez, JoseViteri, SantiagoGasco, AmayaWannesson, LucianoSouglakos, JohnJimeno, JoseRosell, Rafael
- [7] Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression[J]. PLOS ONE, 2009, 4 (05):Rosell, RafaelPerez-Roca, LaiaJavier Sanchez, JoseCobo, ManuelMoran, TeresaChaib, ImaneProvencio, MarianoDomine, ManuelAngeles Sala, MariaJimenez, UlpianoDiz, PilarBarneto, IsidoroAntonio Macias, Josede las Penas, RamonCatot, SilviaIsla, DoloresMiguel Sanchez, JoseIbeas, RafaelLopez-Vivanco, GuillermoOramas, JuanaMendez, PedroReguart, NoemiBlanco, RemeiTaron, Miquel
- [8] OUTCOME IN PEMETREXED/CISPLATIN-TREATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS ACCORDING TO MRNA EXPRESSION LEVELS OF BRCA1, TS, AEG1 AND REV3[J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1040 - S1041Massuti, BartomeuLopez-Vivanco, GuillermoMarti, Thomas M.Kotov, IlyaChaib, ImanePonce-Aix, SantiagoGarcia-Campelo, RosarioMiguel Sanchez, JoseArtal, AngelBover, IsabelTaron, MiquelSanchez-Ronco, MariaRolfo, ChristianStahel, RolfRosell, Rafael
- [9] HIGH MRNA EXPRESSION OF LMO4, A BRCA1 DOWNREGULATOR, CORRELATES WITH BETTER PROGNOSIS IN ERLOTINIB-TREATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) WITH EGFR MUTATIONS[J]. ANNALS OF ONCOLOGY, 2012, 23 : 531 - 531Karachaliou, N.Costa, C.Gimenez-Capitan, A.Viteri, S.Gasco, A.Camps, C.Carcereny, E.Sureda, B. MassutiSouglakos, J.Rosell, R.
- [10] Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial[J]. LANCET RESPIRATORY MEDICINE, 2017, 5 (05): : 435 - 444Rosell, RafaelDafni, UraniaFelip, EnriquetaCurioni-Fontecedro, AlessandraGautschi, OliverPeters, SolangeMassuti, BartomeuPalmero, RamonPonce Aix, SantiagoCarcereny, EnricFrueh, MartinPless, MiklosPopat, SanjayKotsakis, AthanasiosCuffe, SineadBidoli, PaoloFavaretto, AdolfoFroesch, PatriziaReguart, NoemiPuente, JavierCoate, LindaBarlesi, FabriceRauch, DanielThomas, MichaelCamps, CarlosGomez-Codina, JoseMajem, MargaritaPorta, RutShah, RiyazHanrahan, EmerKammler, RoswithaRuepp, BarbaraRabaglio, ManuelaKassapian, MarieKarachaliou, NikiTam, RachelShames, David S.Molina-Vila, Miguel A.Stahel, Rolf A.